REPL
Replimune Group, Inc. · Healthcare
7.97
6.67%(-0.57)
Market OpenLast Updated: — ET
52W L: $2.6852W H: $13.24
$8.00
CHG-0.15 (-1.78%)
H$9.15
L$6.51
VOL29M
REPL (1h)
Replimune Group, Inc. · Healthcare
Replimune Group, Inc. (NASDAQ: REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the business's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at approximately
Replimune Group, Inc. (NASDAQ: REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company.
Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Risk and Volatility Replimune Group has a
The mean of analysts' price targets for Replimune Group (REPL) points to a 79.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Leerink Partners 2026 Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 2:20 pm EDT Jefferies 2026 Biotech on the Beach SummitDate: Tuesday, March 10, 20261x1 Meetings Live webcasts of the fireside chat will be available in the Investors section of Replimune's website at www.replimune.com.
The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sarchi Christopher
officer: Chief Commercial Officer
6,500 SH @ $8.01
2026-04-02
Astley-Sparke Philip
director
25,000 SH @ $0.00
2026-02-18
Patel Sushil
director, officer: Chief Executive Officer
200,000 SH @ $0.00
2025-12-19
Xynos Konstantinos
officer: Chief Medical Officer
60,000 SH @ $0.00
2025-12-19
Hill Emily Luisa
officer: Chief Financial Officer
60,000 SH @ $0.00
2025-12-19
Sarchi Christopher
officer: Chief Commercial Officer
35,000 SH @ $0.00
2025-12-19
Schwendenman Andrew
officer: Chief Accounting Officer
10,000 SH @ $0.00
2025-12-19
Dhingra Kapil
director
3,169 SH @ $1.75
2025-12-09